Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UPP1 | Q16831 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PNP | P00491 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8770174 | 0.89 | UPP1 (0.42) | UPP1ALDH1A1TSHRMAPK1NPSR1 | |
| Hept SCHEMBL1732034 | 0.89 | UPP1 (0.40) | UPP1ALDH1A1TSHRMAPK1NPSR1 | |
| SCHEMBL2789609 | 0.89 | UPP1 (0.40) | UPP1ALDH1A1TSHRHPGD | |
| SCHEMBL2036799 | 0.88 | UPP1 (0.39) | UPP1ALDH1A1TSHRMAPK1NPSR1 | |
| SCHEMBL7219920 | 0.87 | ALDH1A1 (0.52) | UPP1ALDH1A1TSHRMAPK1NPSR1 | |
| SCHEMBL9357959 | 0.87 | UPP1 (0.39) | UPP1ALDH1A1TSHRPNP | |
| SCHEMBL9353768 | 0.87 | UPP1 (0.39) | UPP1 | |
| SCHEMBL9353985 | 0.87 | UPP1 (0.49) | UPP1ALDH1A1TSHRMAPK1NPSR1 | |
| SCHEMBL7219572 | 0.86 | ALDH1A1 (0.39) | UPP1ALDH1A1TSHRMAPK1NPSR1 | |
| SCHEMBL9353681 | 0.86 | HPGD (0.38) | UPP1ALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 649 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210008104-A1 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-01-14 | — | — | US | claimed |
| EP-3664811-A2 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2020-06-17 | — | — | EP | claimed |
| CN-111163783-A | Compositions and methods for inhibiting HIV-1 reverse transcriptase | 美国政府卫生与公众服务部 | 2020-05-15 | — | — | CN | claimed |
| WO-2019032749-A2 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2019-02-14 | — | — | WO | claimed |
| US-9487476-B2 | Catechol diethers as potent anti-HIV agents | YALE UNIVERSITY (US) | 2016-11-08 | — | — | US | claimed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | claimed |
| US-20140288017-A1 | CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-25 | — | — | US | claimed |
| EP-2509949-B1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIV GEORGIA (US) | 2014-04-23 | — | — | EP | claimed |
| US-8703801-B2 | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-04-22 | — | — | US | claimed |
| EP-1200097-B1 | METHOD FOR CONTROLLING THE FIDELITY AND THE PROCESSIVITY OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTED AS SUBSTRATES OF THE REVERSE TRANSCRIPTION RESPONSE WITHOUT BLOCKING ITS ELONGATION | VIGILENT TECHNOLOGIES (FR) | 2014-01-08 | — | — | EP | claimed |
| US-6727059-B1 | ADMINISTERING A NUCLEOSIDE ANALOG THAT HAS A 3' HYDROXYL GROUP LOCATED ON THE C3' CARBON OF THE 2'-DEOXYRIBOSE, FOR EXAMPLE DUTP; FOR RETROID VIRUS INFECTIONS SUCH AS HIV; MIXTURE WITH REVERSE TRANSCRIPTASE INHIBITORS SUCH AS AZT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-04-27 | — | — | US | claimed |
| US-6673830-B2 | COMPOUNDS FROM PLANTS OF THE GENUS CALOPHYLLUM, METHODS OF EXTRACTION AND USE AS TREATMENT FOR HUMAN IMMUMODEFICIENCY VIRUS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES | 2004-01-06 | — | — | US | claimed |
| EP-1200097-A2 | METHOD FOR CONTROLLING THE FIDELITY AND THE EXECUTION OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTED AS SUBSTRATES OF THE REVERSE TRANSCRIPTION RESPONSE WITHOUT BLOCKING ITS ELONGATION | Vigilent Technologies (FR) | 2002-05-02 | — | — | EP | claimed |
| EP-1064263-A2 | NONNUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE FOR THE TREATMENT OF HIV-INFECTION | Parker Hughes Institute (US) | 2001-01-03 | — | — | EP | claimed |
| WO-2000067698-A2 | METHOD FOR CONTROLLING THE FIDELITY AND EXECUTION OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTABLE AS SUBSTRATES WITHOUT BLOCKING ITS ELONGATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2000-11-16 | — | — | WO | claimed |
| WO-1999047501-A2 | NONNUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE FOR THE TREATMENT OF HIV-INFECTION | PARKER HUGHES INSTITUTE (US) | 1999-09-23 | — | — | WO | claimed |
| EP-0371139-B1 | 6-SUBSTITUTED ACYCLICPYRIMIDINE NUCLEOSIDE DERIVATIVES AND ANTIVIRAL AGENTS CONTAINING SAME AS ACTIVE INGREDIENTS | MITSUBISHI CHEM IND (JP) | 1994-10-12 | — | — | EP | claimed |
| US-5112835-A | 6-SUBSTITUTED ACYCLOPYRIMIDINE NUCLEOSIDE DERIVATIVES AND ANTIVIRAL AGENTS CONTAINING THE SAME AS ACTIVE INGREDIENT THEREOF | MITSUBISHI KASEI CORPORATION (JP) | 1992-05-12 | — | — | US | claimed |
| EP-0484071-A2 | Synergism of HIV reverse transcriptase inhibitors | MERCK & CO. INC. (US) | 1992-05-06 | — | — | EP | claimed |
| EP-0371139-A1 | 6-SUBSTITUTED ACYCLICPYRIMIDINE NUCLEOSIDE DERIVATIVES AND ANTIVIRAL AGENTS CONTAINING SAME AS ACTIVE INGREDIENTS | Mitsubishi Chemical Corporation (JP) | 1990-06-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288017-A1 | CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS | COMT, NNMT, PNMT | UPP1 414/4885ALDH1A1 572/4885TSHR 4865/4885 |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | UPP1 309/4885ALDH1A1 1200/4885TSHR 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.